In the News

Countermeasures to Oncology Trial Failures.

Just as drug products have become increasingly complex, regulatory and payer demands have added complexities and costs to drug development.

Vicki Anastasi discusses how a merger or acquisition can impact your medical device’s postmarket surveillance strategy.

Examining the deficits in current risk mitigation approaches.

The rising risk of errors, particularly those with complex sources that may be difficult to ascertain in large organizations.

In this article Dr. Martin Lachs explains about ongoing clinical trials in the oncology area.

Deriving methodology standards for clinical trials through a review of research studies.

Major trends in drug development will reshape the global investigative site landscape.

Biomarkers are becoming an essential part of the drug discovery and development process.

Hear perspectives on utilizing historical data and employing clinically meaningful outcomes in a clinical trial design.